A Phase 1 Trial of SGN-CD33A in Patients with CD33-Positive Acute Myeloid Leukemia
SEGE 1913 | 13-1393
Disease(s): Leukemia, Acute Myeloid (AML)
See full trial information
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
A Phase III Randomized Clinical Trial of Pembrolizumab (MK-3475) versus Paclitaxel, Docetaxel or Vinflunine in Subjects with Recurrent or Progressive Metastatic Urothelial Cancer
MRK 1814 | 15-031
Disease(s): Bladder, Urethral
See full trial information
A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib or Placebo for Patients with Resected State III Colon Cancer
CALGB 80702 | CC979
Disease: Colorectal
See full trial information
A randomized phase II trial for patients with p16 positive, non-smoking associated, locoregionally advanced oropharyngeal cancer
NRG HN002 | 15-086
Disease: Head & Neck
See full trial information
A Phase II Clinical Trial of Single Agent Pembrolizumab (MK-3475) in Subjects with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Who Have Failed Platinum and Cetuximab
MRK 1314 | 14-1442
Disease: Head & Neck
See full trial information
Phase I Dose Escalation Study of Stereotactic Body Radiotherapy for p16 Negative Squamous Cell Carcinoma of the Head and Neck in High Risk Patients Who are Ineligible/Refuse Standard of Care Therapy
CASE 8314 | 15-006
Disease: Head & Neck
See full trial information
Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients with Hematological Malignancies
GMCL 1Z14 | 14-963
Disease: Hematologic Malignancy
See full trial information
A phase 2, multicenter, single-arm, open-label study of pomalidomide in combination with low-dose dexamethasone in subjects with relapsed or refractory Multiple Myeloma following lenalidomide-based therapy in the second-line setting
CLGN 1A14 | 14-1374
Disease: Multiple Myeloma
See full trial information
A Multicenter Phase 2 Study of Single-agent Filanesib (ARRY-520) in Patients With Advanced Multiple Myeloma
ARRY 1A14 | 14209
Disease: Multiple Myeloma
See full trial information
Phase 1b/2, Multicenter, Open-label Study of Oprozomib and Dexamethasone in Combination with Lenalidomide or Oral Cyclophosphamide in Patients with Newly Diagnosed Multiple Myeloma
ONYX 1A13 | 14-231
Disease: Multiple Myeloma
See full trial information
Phase II Randomized Study of survival rate of two different drugs in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Dependent versus Best Supportive Care (BSC) in MDS Patients with Low and Intermediate-1 Risk Disease Transfusion-Independent
MDCC 1914 | 14-1479
Disease: Myelodysplastic Syndrome (MDS)
See full trial information
A Phase 1b/2 Study of OMP-59R5 in Combination with Nab-Paclitaxel and Gemcitabine in Subjects with Previously Untreated Stage IV Pancreatic Cancer ALPINE: Antibody therapy in first-Line Pancreatic cancer Investigating anti-Notch Efficacy and safety
OMP 1213 | 14-124
Disease: Pancreas
See full trial information
A Phase I single arm study to assess the safety and efficacy of Pomalidomide in patients with bleeding due to Hereditary Hemorrhagic Telangiectasia and Refractory Angiodysplasia
CASE 4Z14 | 14-786
Diseases: Telangiectasia, Vascular Ectasia
See full trial information
Search our clinical trials database to see all currently open cancer trials.
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy